Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy
ASAHI KAISEI CRP UNSP/ADR (AHKSY)
NASDAQ:AMEX Investor Relations:
asahi-kasei.co.jp/asahi/en/ir
Company Research
Source: Business Wire
Aicuris’s three antiviral assets complement Asahi Kasei’s therapy portfolioAicuris revenue expected to reach $500 million by 2030FDA has granted Priority Review for the pritelivir New Drug Application. Prescription Drug User Fee Act (PDUFA) target date is Q4 2026 TOKYO--(BUSINESS WIRE)--Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective Cures AG (Aicuris), a German-based biopharmaceutical company. This closing marks a key step in accelerating the company’s efforts to build a global specialty pharmaceutical platform by expanding further into severe infectious diseases.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420808996/en/Aicuris Therapeutics Asset Overview“The completion of the Aicuris acquisition reflects the deliberate execution of our pharmaceutical strategy and strengthens our position in infectious diseases, a core area where we see sus
Show less
Read more
Impact Snapshot
Event Time:
AHKSY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AHKSY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AHKSY alerts
High impacting ASAHI KAISEI CRP UNSP/ADR news events
Weekly update
A roundup of the hottest topics
AHKSY
News
- Asahi Kasei Completes Acquisition of Aicuris to Advance Its Global Pharmaceutical Strategy [Yahoo! Finance]Yahoo! Finance
- Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune Diseases [Yahoo! Finance]Yahoo! Finance
- Asahi Kasei Announces Initiation of Phase I Clinical Trial for Novel Peptide Candidate Targeting Autoimmune DiseasesBusiness Wire
- Asahi Kasei (AHKSY) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Is It Too Late To Consider Asahi Kasei (TSE:3407) After A 73% One-Year Surge? [Yahoo! Finance]Yahoo! Finance